RT Journal Article SR Electronic T1 Impact of Histological Features on Adjuvant Chemotherapy for Invasive Intraductal Papillary Mucinous Carcinoma JF Anticancer Research JO Anticancer Res FD International Institute of Anticancer Research SP 2645 OP 2655 DO 10.21873/anticanres.15742 VO 42 IS 5 A1 TAKAAKI FURUKAWA A1 MANABU TAKAMATSU A1 YOSUKE INOUE A1 TAKESHI OKAMOTO A1 TAKAFUMI MIE A1 YUTO YAMADA A1 TSUYOSHI TAKEDA A1 AKIYOSHI KASUGA A1 MASATO MATSUYAMA A1 TAKASHI SASAKI A1 MASATO OZAKA A1 ATSUSHI OBA A1 HIROMICHI ITO A1 YOSHIHIRO ONO A1 TAKAFUMI SATO A1 YU TAKAHASHI A1 AKIO SAIURA A1 NAOKI SASAHIRA YR 2022 UL http://ar.iiarjournals.org/content/42/5/2645.abstract AB Background/Aim: This study evaluated the efficacy of adjuvant chemotherapy (AC) for intraductal papillary mucinous carcinoma (IPMC). Patients and Methods: We retrospectively analyzed patients who underwent pancreatectomy for invasive IPMC from January 2007 to June 2020. We evaluated outcomes of AC in the entire cohort and in patients with known prognostic factors. Results: A total of 51 patients with invasive IPMC underwent surgery, of which 35 received AC. In the entire cohort, there was no significant difference in median overall survival (OS) between the AC and surgery alone (SA) group [hazard ratio (HR)=0.54; p=0.232]. For patients with poorly differentiated adenocarcinoma, median OS was significantly longer in the AC group (HR=0.27; p=0.022). For patients with lymph node metastasis, median OS was significantly higher in the AC group (HR=0.07; p<0.001). Conclusion: AC may be effective for selected invasive IPMC patients.